Results 71 to 80 of about 40,707 (134)

Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis. [PDF]

Front Immunol
Li S, He T, Chen J, Liu T, Zhao X, Dang J.   +5 more
europepmc   +1 more source

Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report. [PDF]

Cancer Rep (Hoboken)
Patel R, Post-Zwicker L, Kaur V.
europepmc   +1 more source

Pulmonary veno-occlusive disease after immune checkpoint inhibitor therapy: an autopsy case report. [PDF]

Eur Heart J Case Rep
Hasegawa-Tamba S, Sato T, Arai T, Nakano S.   +3 more
europepmc   +1 more source

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis. [PDF]

Dermatol Ther (Heidelb)
Zarańska K, Kamińska-Winciorek G, Cortez AJ, Wąsik G, Gajda M.   +4 more
europepmc   +1 more source

Immunogenic Cell Death: Unlocking New Frontiers in Cancer Immunotherapy. [PDF]

Cancer Innov
Yaacoub K.
europepmc   +1 more source

The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic review. [PDF]

BMC Cancer
Wu M, Larkin J, Furness A, Stavropoulou C.   +3 more
europepmc   +1 more source

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. [PDF]

Oncologist
AlSharif H, Danchine V, Deekollu K, Hasanov M, Wu R, Haykal T, Faieta A, Verschraegen CF.   +7 more
europepmc   +1 more source

Circulating proteins as biomarkers of response to cancer immunotherapy (Review). [PDF]

Int J Oncol
Pinard C, Ginzac A, Abrial C, Durando X, Radosevic-Robin N.   +4 more
europepmc   +1 more source